0203 GMT - A high-severity influenza season in the U.S. could benefit vaccine makers including Australia's CSL, Morgan Stanley analyst David L. Bailey says. He points out that the U.S. CDC has designated its first high-severity season since 2017-18, with hospitalization rates at the end of February sitting at their highest levels since 2010-11. Bailey doesn't speculate on the degree to which vaccine demand could rise or the extent to which CSL and others could benefit. However, he thinks that vaccination rates may rise. CSL's fiscal first-half influenza vaccine sales fell 15% amid lower U.S. vaccination rates for people aged 15-64, he adds. Morgan Stanley has an overweight rating and A$313.00 target price on the stock, which is down 0.8% at A$253.20. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
March 20, 2025 22:03 ET (02:03 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。